<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02811484</url>
  </required_header>
  <id_info>
    <org_study_id>1512016843</org_study_id>
    <nct_id>NCT02811484</nct_id>
  </id_info>
  <brief_title>Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes</brief_title>
  <acronym>Dexlar</acronym>
  <official_title>Efficacy of Exenatide-LAR Alone and in Combination With Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Uncontrolled Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see what the effects of using one or two additional diabetes&#xD;
      drugs (dapagliflozin and exenatide-LAR) are on blood sugar levels in patients who are taking&#xD;
      insulin. This research study is being done to investigate which of these commonly-used&#xD;
      medications, medication combinations or increasing insulin dose is better.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center prospective, randomized, placebo-controlled trial in overweight/obese&#xD;
      patients with insulin treated uncontrolled type 2 diabetes&#xD;
&#xD;
      Eligible subjects willing to participate in the study will be randomized to one of 3&#xD;
      treatment groups:&#xD;
&#xD;
      Group 1: Insulin titration + behavioral therapy Basal insulin titration upto 12 weeks with 2&#xD;
      U increment every 3 days (Fasting glucose goal &lt;110) based on self-monitored blood glucose.&#xD;
&#xD;
      After 12 weeks, patients with HbA1c &gt;8% will switch to a basal bolus regimen.&#xD;
&#xD;
      Group 2: Exenatide-LAR 2mg q week x 24 weeks + Dapagliflozin placebo x 52 weeks + titrated&#xD;
      basal insulin +behavioral therapy.&#xD;
&#xD;
      Group 3: Exenatide-LAR 2mg q week x 24 weeks plus Dapagliflozin 5mg QD x 2 weeks followed by&#xD;
      10mg QD x22 weeks +titrated basal insulin + behavioral therapy.&#xD;
&#xD;
      Behavioral therapy will be delivered by registered dietitians and will include the BMIQ&#xD;
      program -a web based medical weight loss program.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Inability to enroll due to the widespread use of both classes of drugs in patients with T2DM,&#xD;
    including those on concomitant insulin therapy.&#xD;
  </why_stopped>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>baseline, 24 weeks</time_frame>
    <description>To determine the efficacy of Exenatide-LAR and Exenatide-LAR plus dapagliflozin in lowering HbA1c compared with insulin titration in obese, insulin treated subjects with uncontrolled Type 2 Diabetes Mellitus at 24 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight</measure>
    <time_frame>baseline, 24 weeks</time_frame>
    <description>To determine the effect of Exenatide-LAR and Exenatide-LAR plus dapagliflozin vs insulin titration on body weight in obese, insulin treated subjects with uncontrolled T2DM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist circumference</measure>
    <time_frame>baseline, 24 weeks</time_frame>
    <description>To determine the effect of Exenatide-LAR and Exenatide-LAR plus dapagliflozin vs insulin titration on waist circumference in obese, insulin treated subjects with uncontrolled T2DM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting glucose</measure>
    <time_frame>baseline, 24 weeks</time_frame>
    <description>To determine the effect of Exenatide-LAR and Exenatide-LAR plus dapagliflozin vs insulin titration on fasting glucose (FG) in obese, insulin treated subjects with uncontrolled T2DM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting lipids</measure>
    <time_frame>baseline, 24 weeks</time_frame>
    <description>To determine the effect of Exenatide-LAR and Exenatide-LAR plus dapagliflozin vs insulin titration on fasting lipids in obese, insulin treated subjects with uncontrolled T2DM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>baseline, 24 weeks</time_frame>
    <description>To determine the effect of Exenatide-LAR and Exenatide-LAR plus dapagliflozin vs insulin titration on blood pressure in obese, insulin treated subjects with uncontrolled T2DM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total dose insulin</measure>
    <time_frame>baseline, 24 weeks</time_frame>
    <description>To determine the effect of Exenatide-LAR and Exenatide-LAR plus dapagliflozin vs insulin titration on total dose insulin in obese, insulin treated subjects with uncontrolled T2DM</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Insulin titration and behavioral therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Exenatide-LAR plus Dapagliflozin placebo, basal insulin titration, and behavioral therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exenatide-LAR plus Dapagliflozin, basal insulin titration, and behavioral therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide-LAR plus Dapagliflozin placebo</intervention_name>
    <description>Exenatide-LAR 2 mg every week x 24 weeks plus Dapagliflozin placebo x 52 weeks and behavioral therapy.</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Bydureon</other_name>
    <other_name>Farxiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide-LAR plus Dapagliflozin</intervention_name>
    <description>Exenatide-LAR 2 mg every week x 24 weeks plus Dapagliflozin 5 mg x 2 weeks, then 10 mg for 22 weeks and behavioral therapy.</description>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>Bydureon</other_name>
    <other_name>Farxiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Titration</intervention_name>
    <description>Basal insulin titration up to 12 weeks followed by basal-bolus regimen in those with HbA1c&gt;8%</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>Lantus, Levemir, Novolog, Lispro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral Therapy</intervention_name>
    <description>Subjects will be seen by a registered dietitian and receive nutritional and lifestyle counseling according to a web-based weight management program.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Diagnosis of Type 2 diabetes&#xD;
&#xD;
          -  BMI ≥27kg/m^2&#xD;
&#xD;
          -  Hemoglobin A1C 8-12%&#xD;
&#xD;
          -  English speaking&#xD;
&#xD;
          -  provided written consent&#xD;
&#xD;
          -  on a stable dose of metformin and/or glitazone and/or alpha-glucosidase inhibitors for&#xD;
             ≥ to 8 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of type 1 diabetes&#xD;
&#xD;
          -  fasting c-peptide &lt;.8 ng/ml&#xD;
&#xD;
          -  eGFR &lt;60 ml/min/1.73 m^2&#xD;
&#xD;
          -  urine albumin-to-creatinine ratio greater or equal to 300 mg/g&#xD;
&#xD;
          -  AST/ALT greater or equal to 2.5 upper limits of normal&#xD;
&#xD;
          -  history of infectious liver disease (HBV, HCV)&#xD;
&#xD;
          -  creatine kinase greater or equal to 3 times the upper limits of normal&#xD;
&#xD;
          -  unstable or serious cardiovascular, renal, or hepatic disease&#xD;
&#xD;
          -  symptoms of severely uncontrolled diabetes&#xD;
&#xD;
          -  history of more than 1 episode of severe/major hypoglycemia within 6 months,&#xD;
             active/history of bladder cancer&#xD;
&#xD;
          -  female patients who are pregnant or intending to become pregnant&#xD;
&#xD;
          -  women who are breastfeeding&#xD;
&#xD;
          -  personal/family history of medullary thyroid cancer or MEN2&#xD;
&#xD;
          -  fasting triglyceride levels &gt; 500 mg/dl&#xD;
&#xD;
          -  history of confirmed pancreatitis&#xD;
&#xD;
          -  known hypersensitivity or allergy to exenatide or dapagliflozin&#xD;
&#xD;
          -  are currently enrolled in or discontinued within last 30 days from another study&#xD;
&#xD;
          -  have any other condition that precludes the patient from following and completing the&#xD;
             protocol&#xD;
&#xD;
          -  history of diabetic ketoacidosis&#xD;
&#xD;
          -  anti-diabetes medication other than those listed in the inclusion criteria within 8&#xD;
             weeks of screening&#xD;
&#xD;
          -  history of previous bariatric surgery or planned bariatric surgery during the course&#xD;
             of the study&#xD;
&#xD;
          -  clinically significant abnormal free T4/TSH requiring initiation or adjustment of&#xD;
             thyroid treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alpana P Shukla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Comprehensive Weight Control Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>June 17, 2016</study_first_submitted>
  <study_first_submitted_qc>June 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2016</study_first_posted>
  <last_update_submitted>March 1, 2017</last_update_submitted>
  <last_update_submitted_qc>March 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

